Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Current Liabilities (2016 - 2025)

Fate Therapeutics' Total Current Liabilities history spans 14 years, with the latest figure at $36.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 6.36% year-over-year to $36.1 million; the TTM value through Dec 2025 reached $36.1 million, down 6.36%, while the annual FY2025 figure was $36.1 million, 6.36% down from the prior year.
  • Total Current Liabilities reached $36.1 million in Q4 2025 per FATE's latest filing, up from $28.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $114.1 million in Q4 2022 to a low of $28.1 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $60.6 million, with a median of $45.0 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 279.46% in 2021, then plummeted 65.72% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $81.3 million in 2021, then soared by 40.31% to $114.1 million in 2022, then tumbled by 65.72% to $39.1 million in 2023, then dropped by 1.46% to $38.5 million in 2024, then decreased by 6.36% to $36.1 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Total Current Liabilities are $36.1 million (Q4 2025), $28.1 million (Q3 2025), and $28.7 million (Q2 2025).